Alaunos Therapeutics (TCRT) director receives 6,274-share stock grant in lieu of fees

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Postma Robert W reported acquisition or exercise transactions in this Form 4 filing.

Alaunos Therapeutics director Robert W. Postma reported a stock-based compensation grant. On April 29, 2026, he received 6,274 shares of Alaunos Therapeutics common stock at $2.59 per share, issued in lieu of board fees. Following this grant, he directly holds 50,146 shares of common stock.

In addition to his direct holdings, Postma has indirect ownership interests, including 62,416 shares held by WaterMill Asset Management Corp., where he serves as principal, and 24 shares held in his spouse’s IRA. The filing does not show any open-market purchases or sales, only this compensation-related award and updated ownership positions.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Postma Robert W

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,274	$2.59	$16K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 50,146 shares (Direct, null); Common Stock — 24 shares (Indirect, By spouse's IRA)

Footnotes (1)

Represents shares of common stock issued in lieu of board fees. The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill.

Key Figures

Stock grant: 6,274 shares Grant price: $2.59 per share Direct holdings after grant: 50,146 shares +2 more

5 metrics

Stock grant 6,274 shares Common stock granted in lieu of board fees on April 29, 2026

Grant price $2.59 per share Value per share for 6,274-share compensation grant

Direct holdings after grant 50,146 shares Common stock directly owned by Robert W. Postma following the reported transaction

Indirect holdings via WaterMill 62,416 shares Common stock held by WaterMill Asset Management Corp., where Postma is principal

Spouse IRA holdings 24 shares Common stock held indirectly through spouse’s IRA

Key Terms

in lieu of board fees, Grant, award, or other acquisition, indirect ownership, Common Stock, +1 more

5 terms

in lieu of board fees financial

"Represents shares of common stock issued in lieu of board fees."

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

indirect ownership financial

"ownership_type: indirect; nature_of_ownership: By WaterMill Asset Management Corp."

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/01/2026 - 04:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Postma Robert W

(Last)

(First)

(Middle)

C/O ALAUNOS THERAPEUTICS, INC.

501 E. LAS OLAS BLVD. SUITE 300

(Street)

FORT LAUDERDALE

FLORIDA

33301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/29/2026		A		6,274⁽¹⁾	A	$2.59	50,146	D
Common Stock								24	I	By spouse's IRA
Common Stock								62,416⁽²⁾	I	By WaterMill Asset Management Corp.⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock issued in lieu of board fees.

2. The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill.

	/s/ Postma, Robert W	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Alaunos Therapeutics (TCRT) director Robert Postma report?

Robert W. Postma reported receiving 6,274 shares of Alaunos Therapeutics common stock. The shares were granted at $2.59 per share as stock-based compensation issued in lieu of board fees, rather than through an open-market purchase or sale.

At what price were the Alaunos Therapeutics (TCRT) shares granted to Robert Postma?

The shares granted to Robert W. Postma were valued at $2.59 per share. This grant, totaling 6,274 shares, was issued as compensation in lieu of board fees, reflecting a non-cash method of paying part of his director compensation.

How many Alaunos Therapeutics (TCRT) shares does Robert Postma hold directly after this filing?

After the reported grant, Robert W. Postma directly owns 50,146 shares of Alaunos Therapeutics common stock. This figure reflects his direct holdings only and excludes additional shares held indirectly through related entities and his spouse’s IRA.

What indirect Alaunos Therapeutics (TCRT) holdings are associated with Robert Postma?

Indirectly, 62,416 Alaunos Therapeutics shares are held by WaterMill Asset Management Corp., where Robert Postma serves as principal, and 24 shares are held in his spouse’s IRA. These positions are reported as indirect ownership interests in the Form 4 filing.

Was the Alaunos Therapeutics (TCRT) Form 4 transaction a market buy or sell by Robert Postma?

The Form 4 does not show an open-market buy or sell by Robert Postma. Instead, it reports a grant of 6,274 shares issued in lieu of board fees, meaning the shares were received as compensation rather than purchased or sold on the market.

What does “issued in lieu of board fees” mean in the Alaunos Therapeutics (TCRT) filing?

“Issued in lieu of board fees” means Robert Postma received 6,274 shares instead of cash for his director fees. This compensates him with equity at $2.59 per share, aligning part of his pay with Alaunos Therapeutics’ stock performance rather than cash payments.